Evidence map›Paper›PMID 36983781›Full record

ArticleLife (Basel, Switzerland)2023

Melanoma and Nevi Subtype Histopathological Characterization with Optical Coherence Tomography.

Cristina L Saratxaga, Aintzane Asumendi, Jesús Gardeazabal, Rosa M Izu, Ana Sanchez, Goikoana Cancho-Galan, Celia Morales, Sergio Lage, Maria D Boyano, Olga M Conde and 1 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Cristina L SaratxagaTECNALIA, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia, C/Geldo. Edificio 700, 48160 Derio, Spain.ORCID 0000-0003-1429-7936
Aintzane AsumendiDepartment of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0002-2156-2323
Jesús GardeazabalBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0001-5938-0835
Rosa M IzuBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0001-6159-6395
Ana SanchezBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Goikoana Cancho-GalanBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Celia MoralesDepartment of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0001-5423-3684
Sergio LageDepartment of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.
Maria D BoyanoDepartment of Cell Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0001-6051-1054
Olga M CondePhotonics Engineering Group, University of Cantabria, 39005 Santander, Spain.ORCID 0000-0002-2471-3051
Estibaliz GarroteTECNALIA, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia, C/Geldo. Edificio 700, 48160 Derio, Spain.
University of the Basque Country · ESBioCruces Health research Institute · ESUniversidad de Cantabria · ES

Funding

Department of Economic Development, Sustainability and the Environment of the Basque Gov-ernment (Spain), ELKARTEK ONKOTOOLS (grant number KK-2020/00069)ECSEL JU ASTONISH (grant number 692470)Spanish Ministry of Science and Education,CERVERA AI4ES (grant number CER-20211030)
6 · The paper itself

Abstract

backgroundMelanoma incidence has continued to rise in the latest decades, and the forecast is not optimistic. Non-invasive diagnostic imaging techniques such as optical coherence tomography (OCT) are largely studied; however, there is still no agreement on its use for the diagnosis of melanoma. For dermatologists, the differentiation of non-invasive (junctional nevus, compound nevus, intradermal nevus, and melanoma in-situ) versus invasive (superficial spreading melanoma and nodular melanoma) lesions is the key issue in their daily routine.

methodsThis work performs a comparative analysis of OCT images using haematoxylin-eosin (HE) and anatomopathological features identified by a pathologist. Then, optical and textural properties are extracted from OCT images with the aim to identify subtle features that could potentially maximize the usefulness of the imaging technique in the identification of the lesion's potential invasiveness.

resultsPreliminary features reveal differences discriminating melanoma in-situ from superficial spreading melanoma and also between melanoma and nevus subtypes that pose a promising baseline for further research.

conclusionsAnswering the final goal of diagnosing non-invasive versus invasive lesions with OCT does not seem feasible in the short term, but the obtained results demonstrate a step forward to achieve this.

Indexed as

CADxHEhistopathologymelanomaOCToptical biopsyoptical propertiesskin cancertextural properties

Identifiers

PMID36983781
PMCPMC10058073
OpenAlexW4321786719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.